9
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T9756 | AZD-9574 | PARP | |
AZD-9574 is a selective inhibitor of PARP1 at the sites of SSBs. AZD-9574 exhibits anti-cancer activities and can be used in studies about HRD+ breast cancer and advanced solid malignancies. | |||
T8806 | Fluzoparib | HS10160,SHR3162 | PARP |
Fluzoparib (SHR3162) is a novel, potent, and orally available inhibitor of PARP, potentially for the treatment of solid tumours. | |||
T2628 | RI-2 | DNA/RNA Synthesis | |
RI-2 is an optimized RAD51 inhibitor with an IC50 of 44.17 μM in the standard DNA binding assay; specifically inhibits HR(Homologous recombination) repair in human cells. | |||
T8880 | PFM01 | Others | |
PFM01 is an inhibitor of MRE11 endonuclease. PFM01 can regulate double-strand break repair (DSBR) by nonhomologous end-joining (NHEJ) versus homologous recombination (HR). | |||
T63228 | Simmiparib | SMOCL-9112 | Apoptosis , PARP |
Simmiparib (SMOCL-9112) is a novel and potent PARP1 and PARP2 inhibitor, a derivative of Olaparib.Simmiparib induces DNA double-strand breaks (DSBs) and cell cycle arrest in homologous recombination repair (HR)-deficient... | |||
T6960L | PU-H71 HCl | PU-H71 HCl(873436-91-0 Free base),Zelavespib HCl | HSP , DNA/RNA Synthesis |
PU-H71 HCl (Zelavespib HCl) is a novel Hsp90 inhibitor, a novel purine-based analog, and a radiosensitizer that may be a promising agent for CIRT. PU-H71 HCL shows antitumor activity in many preclinical models of maligna... | |||
T68398 | MI-223 | ||
MI-223 is an inhibitor of Mcl-1-stimulated homologous recombination (HR) DNA repair, which leads to sensitization of cancer cells to hydroxyurea- or olaparib-induced DNA replication stress. | |||
T72560 | Antitumor agent-81 | ||
Antitumor agent-81, a P62-RNF168 agonist with low cytotoxicity, enhances the P62-RNF168 interaction, leading to decreased RNF168-mediated H2A ubiquitination and impaired homologous recombination-mediated DNA repair. Addi... | |||
T74501 | NHEJ inhibitor-1 | ||
NHEJ Inhibitor-1 (Compound C2), a trifunctional Pt(II) complex, mitigates non-homologous end joining (NHEJ)/homologous recombination (HR)-related double strand break (DSB) repairs, combating Cisplatin resistance in non-s... |